Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 804 Results

Title
Intervention Indication Therapeutic Area Year Actions
Apremilast for oral ulcers in active Beh cet’s disease Apremilast (Otezla; CC-10004) Oral ulcers Dental and Oral Health 2018 View  |  Download
AR101 for peanut allergy in children aged 1 – 3 years Palforzia (AR101) Peanut allergy Immunology 2022 View  |  Download
AR101 peanut allergy immunotherapy for adult and paediatric patients Palforzia (AR101) Peanut allergy Immunology 2017 View  |  Download
Arimoclomol for Niemann-Pick Disease type C - add-on therapy Arimoclomol (BRX-345) Niemann-Pick Disease Endocrine Nutritional and Metabolic Disorders , Genetic Disorders , Neurology 2017 View  |  Download
Asciminib for chronic myeloid leukaemia – chronic phase -third line Asciminib (ABL001) Chronic myeloid leukaemia (CML) Haematological Cancer and Lymphomas 2020 View  |  Download
Asinercept (Apocept) for glioblastoma multiforme for first or second line Asunercept (Apocept; APG101) Glioma Neurological Cancer 2017 View  |  Download
ASTX727 for acute myeloid leukaemia ASTX727 Acute lymphoblastic leukaemia (ALL) Haematological Cancer and Lymphomas 2022 View  |  Download
AT406 (Debio 1143) for Ovarian Cancer – neoadjuvant therapy Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Xevinapant (Debio 1143; AT-406) Ovarian cancer Female Reproductive Cancer 2018 View  |  Download
ATB200/AT2221 for Late onset Pompe disease in adults and adolescents over 12 years – first line ATB200/AT2221 Pompe disease Endocrine Nutritional and Metabolic Disorders , Genetic Disorders 2020 View  |  Download
Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectal cancer - third line Atezolizumab (Tecentriq; MPDL3280A) , Cobimetinib (Cotellic; GDC-0973; cobimetinib hemifumarate) Colorectal cancer Gastrointestinal Cancer , Oncology 2017 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications